Guoxin Wu

Merck & Co., Inc., Rahway, NJ, USA (United States), Beijing Information Science & Technology University

Papers

Total Citations

H-Index

About

Guoxin Wu is a researcher whose work bridges the critical intersection of infectious disease pharmacology and advanced robotics. In the biomedical domain, Wu has made significant contributions to the study of HIV latency reversal, a key barrier to curing chronic HIV infection. Their most cited work, an *In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform* (2021, 6 citations), developed an innovative automated system to evaluate how histone deacetylase inhibitors (HDACis) can reactivate dormant HIV reservoirs. This research provides a powerful framework for testing latency-reversing agents, directly addressing the challenge of lifelong antiretroviral therapy. Demonstrating a diverse technical skillset, Wu has also contributed to mechanical engineering through a *Kinematics simulation analysis of a 7-DOF series robot* (2019, 2 citations), which focused on ensuring motion accuracy for advanced manufacturing. While the citation counts are modest, reflecting the specialized and emerging nature of this work, Wu’s research is notable for its methodological innovation—combining automated high-throughput screening with complex pharmacokinetic modeling. This dual expertise in both computational biology and robotics positions Wu as a versatile scientist capable of tackling complex, interdisciplinary problems in drug development and automation.